PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Livsmed's multi-joint laparoscopic instrument ArtiSential continues to drive high revenue growth, but net losses have widened ahead of the STARK surgical robot's commercial launch.
2025 revenue reached KRW 51.19 billion, up 88.7% year over year, but the operating loss remained at KRW 22.64 billion.
Revenue rose to KRW 10.26 billion in Q1 2026 and KRW 12.51 billion in Q2 2026, yet the net loss widened to KRW 11.03 billion in Q2.
Following the December 2025 KOSDAQ listing, equity expanded to KRW 180.87 billion and the debt ratio fell to 11.6%.
The next-generation surgical robot STARK was unveiled in May 2026, with a domestic regulatory application filed and approval targeted within the year.
A supply agreement with HealthTrust, the largest US group purchasing organization, opened access to a network of 1,800 hospitals and 2,500 outpatient surgery centers.
Founded in 2011, Livsmed specializes in developing and manufacturing multi-joint laparoscopic surgical instruments and listed on KOSDAQ in December 2025.
Its core product is ArtiSential, a handheld laparoscopic instrument built on a pin-joint-based 90-degree multi-directional articulation technology, offered in 8mm and 5mm variants. Roughly 80% of current revenue comes from ArtiSential.
Beyond this, the company has commercialized ArtiSeal (a vessel sealer), ArtiStapler (a surgical stapler), and LivsCam (a 3D4K laparoscopic camera system), with ArtiStapler and LivsCam receiving domestic device certification in November 2025, completing a product lineup spanning the full minimally invasive surgical workflow.
The next-generation surgical robot STARK extends this multi-joint technology into a robotic platform. Customers span major hospitals and surgeons domestically and internationally, with more than 640 practicing surgeons using ArtiSential and products in use across roughly 50 countries.
US distribution runs through a supply agreement with HealthTrust, the largest medical device group purchasing organization, granting access to a network of 1,800 hospitals and 2,500 outpatient surgery centers.
Competitively, Intuitive Surgical dominates the market with its da Vinci platform, while Livsmed is positioned among a small group of companies able to enter advanced instrument categories such as vessel sealers and staplers—where Intuitive's patents remain unexpired—owing to remaining patent life of 8 to 19 years on its own technology.
The company also acquired the assets of US-based FlexDex Surgical, absorbing 63 patents, 17 trademarks, 9 designs, manufacturing equipment, and distribution channels, expanding its total IP portfolio to 939 assets as part of a strategy to block alternative technology paths for later entrants.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | — | — | — |
| 2025Q3 | — | — | — |
| 2025Q4 | — | — | — |
| 2026Q1 | ₩10.3B | -₩8.4B | −81.5% |
| 2026Q2 | ₩12.5B | -₩12.2B | −97.5% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2024 | ₩27.1B | -₩26.5B | -₩25.6B | −97.7% | −64.6% | 34.5% |
| 2025 | ₩51.2B | -₩22.6B | -₩22.9B | −44.2% | −12.6% | 11.6% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04
Livsmed's consolidated 2025 revenue came to KRW 51.19 billion, up 88.7% from KRW 27.12 billion in 2024. Over the same period the operating loss narrowed from KRW 26.50 billion to KRW 22.64 billion, and the net loss attributable to owners also eased slightly from KRW 25.58 billion to KRW 22.87 billion.
The operating margin improved from -97.7% in 2024 to -44.2% in 2025, reflecting reduced relative fixed-cost burden as revenue scaled.
On the balance sheet, the December 2025 listing substantially expanded equity from KRW 39.6 billion to KRW 180.87 billion, while the debt ratio fell from 34.5% to 11.6%, improving financial stability.
However, operating cash flow deteriorated from an outflow of KRW 27.66 billion in 2024 to KRW 34.74 billion in 2025, indicating that cash consumption did not slow despite revenue growth.
Moving into 2026, Q1 revenue was KRW 10.26 billion with an operating loss of KRW 8.37 billion and a net loss (owners) of KRW 5.88 billion, followed by Q2 revenue of KRW 12.51 billion but a wider operating loss of KRW 12.19 billion and net loss of KRW 11.03 billion.
This suggests that costs tied to STARK launch preparation, new product certification and marketing, and US market expansion outpaced incremental revenue during the first half of 2026.
The global laparoscopic instrument market is estimated at roughly USD 15.2 billion, growing close to 8% annually, while robotic surgery penetration has advanced to the point that around 20% of US surgical procedures are now performed robotically.
The robotic segment, however, remains dominated by Intuitive Surgical's da Vinci platform, whose end-effector articulation is limited to 60 degrees despite holding roughly 70% global share—a gap later entrants are targeting for differentiation.
In Korea, expanding robotic surgery adoption following the resolution of the medical strike, combined with replacement demand from hospitals whose da Vinci units are approaching a decade of use, is cited as a favorable backdrop.
While many competitors rely on Intuitive's expired 60-degree patents to offer lower-cost alternatives, Livsmed is pursuing differentiation through its own 90-degree multi-joint technology.
On valuation, Samsung Securities noted in a June 16, 2026 report that Livsmed stands to benefit from rising robotic-surgery penetration on the back of its proprietary technology, targeting a quarterly operating breakeven within 2026 supported by fourth-quarter robot approval momentum and diversified new-product sales through its US GPO channel.
At the same time, some industry observers have argued that to secure a meaningful position in a market dominated by da Vinci, the company needs a clearer commercialization timeline and profitability path for its robotic product.
The company unveiled its STARK surgical robot on May 26, 2026, and filed for domestic regulatory approval, stating it expects clearance within this year.
It plans to pursue overseas expansion through further clinical trials, targeting Japanese approval by the end of next year and US and European approval by the end of 2028. CEO Lee Jung-ju stated a goal of making 2026 the first year of annual profitability.
STARK was also shown for the first time internationally at the World Congress of Robotic Surgery (SRS 2026) held in Florida in July 2026, drawing interest from domestic and international surgeons.
New products ArtiStapler and LivsCam completed domestic certification in November 2025 and are expected by the company to contribute to revenue diversification through full commercial launch in 2026.
Separately, a February 2026 report cited the company's own target of KRW 78.5 billion in operating profit and a 24.4% operating margin for 2026.
However, actual first-half 2026 results showed net losses widening even as revenue grew, highlighting a gap between this annual profitability target and the actual first-half earnings trajectory.
Based on its securities registration statement, US revenue was projected to grow from KRW 2.1 billion in 2024 to KRW 5.7 billion in 2025 and KRW 23.1 billion in 2026, with the US revenue share gradually expanding from 7.8% in 2024.
When Livsmed listed in December 2025, its IPO price was set using Intuitive Surgical, Medtronic, and Stryker as comparable companies—firms whose revenue and profit scale exceed Livsmed's by hundreds of times—which sparked debate over valuation appropriateness from the outset.
Following listing, a large capital inflow from the offering substantially expanded shareholders' equity, placing the premium of share price to net asset value in a lower range than immediately after listing.
Market views on valuation diverge: Samsung Securities noted in a June 16, 2026 report that on a price-to-sales basis the stock trades at a meaningful discount to global peers, whereas at the time of listing some questioned the appropriateness of using such large-cap global peers as comparables at all.
As the company has no dividend payment history, dividend-related metrics cannot be meaningfully benchmarked against sector averages.
Ultimately, how to interpret the current price level depends heavily on the timing of STARK's regulatory approval and revenue contribution, as well as the pace of adoption for products beyond ArtiSential.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04
Livsmed holds more than 500 patents built around its 90-degree multi-joint technology and expanded its total IP portfolio to 939 assets through the FlexDex asset acquisition.
It is also counted among a small group of companies able to enter advanced instrument categories such as vessel sealers and staplers, where Intuitive Surgical's patents remain unexpired. This patent strategy can function as an entry barrier against later competitors.
The supply agreement with HealthTrust, the largest US group purchasing organization, provides distribution access to 1,800 hospitals and 2,500 outpatient surgery centers, supporting US market expansion.
With ArtiSeal, ArtiStapler, and LivsCam being commercialized in sequence alongside ArtiSential, the company is moving to reduce reliance on a single product, which could diversify revenue sources and increase value captured per procedure.
Since its unveiling in May 2026, STARK has drawn attention at domestic and international academic conferences for its clinical flexibility and a successful remote-surgery demonstration, and the company has filed for domestic regulatory approval with a target of clearance within the year.
A subscription-style model that lowers the installation-cost barrier has been previewed, aimed at markets da Vinci has not penetrated. If approval and initial installations proceed as planned, the shift from a laparoscopic-instrument company to a broader surgical-platform company could become more visible.
Q2 2026 revenue grew from Q1, yet the operating loss and net loss both widened, indicating that revenue growth has not directly translated into improved earnings. A gap exists between the company's and some brokerages' 2026 annual profitability target and the actual first-half earnings trajectory.
With costs for new product and robot launches still being incurred, uncertainty remains around the timing of margin improvement.
Roughly 80% of revenue is derived from a single product, ArtiSential, meaning changes in demand or pricing for that product can directly affect overall results.
New products such as ArtiSeal, ArtiStapler, and LivsCam have yet to make a substantial revenue contribution, raising questions about the pace of diversification. Samsung Securities has also flagged the ArtiSential-concentrated revenue mix and the recovery trajectory of gross profit margin as key risks.
US approval for STARK is reported to require additional animal testing, and the target timeline has shifted from end-2027 to end-2028, reflecting scheduling uncertainty. Japanese approval is targeted for the end of next year, meaning meaningful overseas robot revenue will likely take time to materialize.
Intuitive Surgical's dominant installed base and brand recognition with da Vinci remain a significant barrier for new entrants.
Since most revenue stems from a single product family, ArtiSential, the emergence of competing products, price competition, or changes in hospital purchasing policy could materially affect overall results. This structural risk is likely to persist until the newer product lineup gains broader adoption.
There is a possibility that domestic approval timing for the STARK robot could slip, and additional procedures such as animal testing have been cited as necessary for US market entry.
If the sequential overseas approval schedule for Japan, the US, and Europe does not proceed as planned, the timing of overseas revenue expansion could be delayed.
With plans for a gradually rising US revenue share while production remains concentrated domestically, US tariff policy or tightened medical device import regulations could affect profitability.
Because the US market is positioned as a core growth axis, the company's cost structure may have relatively limited flexibility to absorb related policy changes.
Check the Q3 2026 earnings release for revenue and earnings trends and the revenue contribution of new products (ArtiStapler, LivsCam).
Confirm whether STARK receives domestic regulatory approval and review the initial installation and revenue-recognition schedule.
Monitor whether the pace of US revenue growth and actual hospital deliveries through the HealthTrust channel align with the projections disclosed in the securities registration statement.
Track the progress of STARK's Japanese regulatory approval and the pace of domestic installation expansion.
Livsmed has rapidly scaled revenue on the strength of its multi-joint patent portfolio and ArtiSential's high growth, but actual earnings through the first half of 2026 show widening net losses even as revenue increases.
The STARK robot has a domestic approval application pending with clearance targeted within the year, followed by a planned sequential rollout to Japan, the US, and Europe, giving the market a relatively clear set of upcoming milestones to watch.
At the same time, a large share of revenue remains concentrated in a single product, ArtiSential, and newer product lines have yet to make a substantial revenue contribution, leaving open questions about the pace of diversification.
The plan to expand US revenue is exposed to external variables such as trade and tariff policy shifts, and the valuation debate surrounding the choice of IPO comparable companies has not been fully settled.
Ultimately, an assessment of this stock requires confirming whether STARK's approval and commercialization timeline proceeds as planned and whether the newer product lineup can meaningfully reduce dependence on ArtiSential.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.